Evaluation of the antianxiety and antidepressant activities of mosapride in Wistar albino rats

Vybhava Krishna, K. L. Bairy, Navin Patil, Sweenly V. Sunny

Research output: Contribution to journalArticle

Abstract

The 5HT4 receptor agonists are antidepressants with a unique mode of action. Many studies have been done on investigational drugs, and mosapride has been shown to have a 5HT3 antagonistic property. In this study, we assessed the potential anxiolytic and antidepressant effects of mosapride on Wistar albino rats. The rats were randomly assigned to two models containing 4 groups of 6 animals each. In the anxiety model, four groups included 0.5 mL of 0.5% carboxymethyl cellulose (CMC), mosapride 1.5 mg/kg, mosapride 3 mg/kg and diazepam 2 mg/kg. They were dosed for 5 days. On the 3rd day, the elevated plus maze (EPM) was conducted, and on the 5th day, the open field (OF) tests were conducted. In the depression model, four groups included 0.5 mL of 0.5% CMC, mosapride 1.5 mg/kg, mosapride 3 mg/kg and imipramine 30 mg/kg. After 3 days of dosing, the forced swim test (FST) was conducted, followed by a washout period of 1 month. Then, the rats were subjected to chronic unpredictable stress with sucrose preference. Compared with the control, the mosapride-treated animals showed significant anxiolytic behavior at both high and low doses in the EPM and OF tests. In the FST, both high and low doses of mosapride reduced immobility. The climbing behavior was prominent at a high dose of mosapride, whereas swimming was prominent at a low dose. In the chronic stress model, both doses of mosapride preserved sucrose preference comparable to imipramine. These findings suggest that mosapride has anxiolytic and antidepressant activities at clinically used doses.

Original languageEnglish
Article number20180089
JournalJournal of Basic and Clinical Physiology and Pharmacology
Volume30
Issue number4
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

Antidepressive Agents
Wistar Rats
Anti-Anxiety Agents
Carboxymethylcellulose Sodium
Imipramine
Sucrose
mosapride
Investigational Drugs
Diazepam
Anxiety
Depression

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Drug Discovery

Cite this

@article{20ae933e00d34dbba7b1632ef980281c,
title = "Evaluation of the antianxiety and antidepressant activities of mosapride in Wistar albino rats",
abstract = "The 5HT4 receptor agonists are antidepressants with a unique mode of action. Many studies have been done on investigational drugs, and mosapride has been shown to have a 5HT3 antagonistic property. In this study, we assessed the potential anxiolytic and antidepressant effects of mosapride on Wistar albino rats. The rats were randomly assigned to two models containing 4 groups of 6 animals each. In the anxiety model, four groups included 0.5 mL of 0.5{\%} carboxymethyl cellulose (CMC), mosapride 1.5 mg/kg, mosapride 3 mg/kg and diazepam 2 mg/kg. They were dosed for 5 days. On the 3rd day, the elevated plus maze (EPM) was conducted, and on the 5th day, the open field (OF) tests were conducted. In the depression model, four groups included 0.5 mL of 0.5{\%} CMC, mosapride 1.5 mg/kg, mosapride 3 mg/kg and imipramine 30 mg/kg. After 3 days of dosing, the forced swim test (FST) was conducted, followed by a washout period of 1 month. Then, the rats were subjected to chronic unpredictable stress with sucrose preference. Compared with the control, the mosapride-treated animals showed significant anxiolytic behavior at both high and low doses in the EPM and OF tests. In the FST, both high and low doses of mosapride reduced immobility. The climbing behavior was prominent at a high dose of mosapride, whereas swimming was prominent at a low dose. In the chronic stress model, both doses of mosapride preserved sucrose preference comparable to imipramine. These findings suggest that mosapride has anxiolytic and antidepressant activities at clinically used doses.",
author = "Vybhava Krishna and Bairy, {K. L.} and Navin Patil and Sunny, {Sweenly V.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1515/jbcpp-2018-0089",
language = "English",
volume = "30",
journal = "Journal of Basic and Clinical Physiology and Pharmacology",
issn = "0792-6855",
publisher = "Freund Publishing House Ltd",
number = "4",

}

Evaluation of the antianxiety and antidepressant activities of mosapride in Wistar albino rats. / Krishna, Vybhava; Bairy, K. L.; Patil, Navin; Sunny, Sweenly V.

In: Journal of Basic and Clinical Physiology and Pharmacology, Vol. 30, No. 4, 20180089, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the antianxiety and antidepressant activities of mosapride in Wistar albino rats

AU - Krishna, Vybhava

AU - Bairy, K. L.

AU - Patil, Navin

AU - Sunny, Sweenly V.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The 5HT4 receptor agonists are antidepressants with a unique mode of action. Many studies have been done on investigational drugs, and mosapride has been shown to have a 5HT3 antagonistic property. In this study, we assessed the potential anxiolytic and antidepressant effects of mosapride on Wistar albino rats. The rats were randomly assigned to two models containing 4 groups of 6 animals each. In the anxiety model, four groups included 0.5 mL of 0.5% carboxymethyl cellulose (CMC), mosapride 1.5 mg/kg, mosapride 3 mg/kg and diazepam 2 mg/kg. They were dosed for 5 days. On the 3rd day, the elevated plus maze (EPM) was conducted, and on the 5th day, the open field (OF) tests were conducted. In the depression model, four groups included 0.5 mL of 0.5% CMC, mosapride 1.5 mg/kg, mosapride 3 mg/kg and imipramine 30 mg/kg. After 3 days of dosing, the forced swim test (FST) was conducted, followed by a washout period of 1 month. Then, the rats were subjected to chronic unpredictable stress with sucrose preference. Compared with the control, the mosapride-treated animals showed significant anxiolytic behavior at both high and low doses in the EPM and OF tests. In the FST, both high and low doses of mosapride reduced immobility. The climbing behavior was prominent at a high dose of mosapride, whereas swimming was prominent at a low dose. In the chronic stress model, both doses of mosapride preserved sucrose preference comparable to imipramine. These findings suggest that mosapride has anxiolytic and antidepressant activities at clinically used doses.

AB - The 5HT4 receptor agonists are antidepressants with a unique mode of action. Many studies have been done on investigational drugs, and mosapride has been shown to have a 5HT3 antagonistic property. In this study, we assessed the potential anxiolytic and antidepressant effects of mosapride on Wistar albino rats. The rats were randomly assigned to two models containing 4 groups of 6 animals each. In the anxiety model, four groups included 0.5 mL of 0.5% carboxymethyl cellulose (CMC), mosapride 1.5 mg/kg, mosapride 3 mg/kg and diazepam 2 mg/kg. They were dosed for 5 days. On the 3rd day, the elevated plus maze (EPM) was conducted, and on the 5th day, the open field (OF) tests were conducted. In the depression model, four groups included 0.5 mL of 0.5% CMC, mosapride 1.5 mg/kg, mosapride 3 mg/kg and imipramine 30 mg/kg. After 3 days of dosing, the forced swim test (FST) was conducted, followed by a washout period of 1 month. Then, the rats were subjected to chronic unpredictable stress with sucrose preference. Compared with the control, the mosapride-treated animals showed significant anxiolytic behavior at both high and low doses in the EPM and OF tests. In the FST, both high and low doses of mosapride reduced immobility. The climbing behavior was prominent at a high dose of mosapride, whereas swimming was prominent at a low dose. In the chronic stress model, both doses of mosapride preserved sucrose preference comparable to imipramine. These findings suggest that mosapride has anxiolytic and antidepressant activities at clinically used doses.

UR - http://www.scopus.com/inward/record.url?scp=85069759184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069759184&partnerID=8YFLogxK

U2 - 10.1515/jbcpp-2018-0089

DO - 10.1515/jbcpp-2018-0089

M3 - Article

C2 - 31318691

AN - SCOPUS:85069759184

VL - 30

JO - Journal of Basic and Clinical Physiology and Pharmacology

JF - Journal of Basic and Clinical Physiology and Pharmacology

SN - 0792-6855

IS - 4

M1 - 20180089

ER -